Takeda-6d |
カタログ番号GC49700 |
Takeda-6D (化合物 6d) は、経口で有効な強力な BRAF/VEGFR2 阻害剤であり、IC50 値はそれぞれ 7.0 および 2.2 nM です。 Takeda-6D は、293/KDR および VEGF 刺激 HUVEC 細胞で VEGFR2 経路を抑制することにより、血管新生を抑制します。Takeda-6D は、ERK1/2 リン酸化の有意な抑制を示します。 Takeda-6D は抗腫瘍活性を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1125632-93-0
Sample solution is provided at 25 µL, 10mM.
Takeda-6d is a dual inhibitor of RAF kinases and VEGFR2.1 It inhibits wild-type B-RAF, mutant B-RAFV600E, and C-RAF (IC50s = 12, 7, and 1.5 nM, respectively), as well as VEGFR2 (IC50 = 2.8 nM). Takeda-6d is selective for these kinases over a panel of 19 additional kinases (IC50s = >1,000 nM) but does inhibit FGFR3, PDGFRα, and PDGFRβ (IC50s = 22, 12, and 5.5 nM, respectively). It inhibits MEK and ERK1/2 phosphorylation in several colon cancer and melanoma cell lines expressing B-RAFV600E when used at concentrations ranging from 100 to 1,600 nM, as well as inhibits VEGF-A-induced phosphorylation of VEGFR2 in VEGFR2-overexpressing KDR cells (IC50 = 0.53 nM). Takeda-6d (10 mg/kg) reduces tumor volume in an A375 melanoma mouse xenograft model.
1.Okaniwa, M., Hirose, M., Imada, T., et al.Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffoldsJ. Med. Chem.55(7)3452-3478(2012)
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *